RCT: Final analysis of efficacy and safety of single-dose J&J vaccine.
10 Feb, 2022 | 10:03h | UTCFinal Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S – New England Journal of Medicine
Commentary on Twitter
A single injection of the Ad26.COV2.S Covid-19 vaccine showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical #COVID19. #IDTwitter https://t.co/0VhaEUtmwq pic.twitter.com/04QqSyYwNI
— NEJM (@NEJM) February 9, 2022